Immunotherapy was long considered as an attractive modality in the treatment of lung cancer. However, clinical successes were hampered by the inability to achieve potent activation of the antitumor immune system and effectively overcome the immune suppressive environment associated with lung cancer. Recent advances in cancer immunotherapy demonstrate that these limitations can be surmounted. In this review, we discuss the recent advances in immunotherapy of lung cancer and their potential implication for management of this disease. (J Lung Cancer 2012;11(1):1 11)
INTRODUCTION
Lung cancer is one of the most frequent types of cancer. IFN-γ can induce programmed cell death and, together with interleukin (IL)-12 it was implicated in apoptosis via production of reactive oxygen species and nitrogen intermediates (3) . IFN-γ can modulate a p53-independent apoptotic pathway by inducing select apoptosis-related genes like bak (4) . IFN-γ also increased the sensitivity of tumor cell lines to tumor necrosis factor-α (TNF-α)-mediated and anti-Fas antibody-mediated cell death (4) . It was reported that the combination of TNF-α/ IFN-γ induces apoptotic cell death through a p53-independent, but c-myc-dependent pathway in a NSCLC cell line (5 (12) . Decreased IFN-γ was found not only in the NK cells, but also in the T cells from lung cancer patients (13, 14) .
MECHANISMS OF TUMOR ESCAPE FROM IMMUNE CONTROL
Tumors have a variety of mechanisms by which they evade host immune surveillance. These mechanisms affect a large 
TUMOR ASSOCIATED ANTIGENS IN LUNG CANCER
Although lung cancer is typically not considered as immunogenic tumor, a number of tumor associated antigens (TAA) were described in lung cancer. In 79 patients with lung cancer melanoma-associated antigen (MAGE)-3 was expressed in 42% of patients, sarcoma antigen NY-SAR-35 (33%), cancer-testis antigen NY-ESO-1 (30%), MAGE-1 (27%), cancer testis (CT)
antigen CT-7 (20%), MAGE-4 (19%), CT antigen LAGE-1 (16%), and MAGE-10 (14%) ( Table 1) . Thirteen CT antigens were tested by reverse transcriptase-polymerase chain reaction; and out of these 73% tissues samples expressed at least one CT antigen. Other tissues co-expressed from 2 to 9 CT antigens. This study showed the multitude of existing lung cancer antigens. However, 27% of patients had no expression of CT antigens in lung tissues (34) . Expression of MAGE-A3/6 was found in 50% of patients with NSCLC (including squamous cell carcinoma and adenocarcinoma); whereas NY-ESO-1 was expressed in 18.2% of cases (35) . MAGE-A3/6 was 
THERAPEUTIC APPROACHES TARGETING TAA IN LUNG CANCER
Depending on the nature of TAA, two major approaches are used for cancer immune therapy. The first approach utilizes defined TAA. In this case, the specific peptide representing TAA can be delivered to the patients either directly or in combination with different adjuvants, or loaded on DC. TAA can be delivered in the form of cDNA or RNA that are loaded, transfected, or transduced to DC.
Since MUC1 is expressed on the cell surface of many common adenocarcinomas, including lung cancer, it was used in immune therapy. A phase I study, using a modified vaccinia virus (Ankara) expressing human MUC1, which also contains a coding sequence for human IL-2 (TG4010), revealed a safe toxicity profile and some clinical activity (46) . 
REGULATION OF IMMUNE RESPONSES AND TUMOR MICROENVIRONMENT AS A WAY TO IMPROVE THE EFFECT OF CANCER IMMUNE THERAPY
Since tumor microenvironment is highly immune suppress- 
CONCLUSION
Cancer immune therapy went a long way from vague promise to clinical reality these days. We learned how to generate reasonably potent cancer vaccine and to prepare T cells for adoptive therapy. The challenge now is to develop strategies to overcome the negative effect of immune suppressive network present in cancer patients. Recent successes in the regulation of tumor microenvironment indicate that this challenge will be successfully met and cancer immune therapy will become an active part of therapy of lung cancer.
